image
Healthcare - Medical - Instruments & Supplies - NASDAQ - JE
$ 16.11
-2.78 %
$ 1.74 B
Market Cap
-12.49
P/E
1. INTRINSIC VALUE

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.[ Read More ]

The intrinsic value of one NVCR stock under the base case scenario is HIDDEN Compared to the current market price of 16.1 USD, NovoCure Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVCR

image
FINANCIALS
509 M REVENUE
-5.30%
-233 M OPERATING INCOME
-160.12%
-207 M NET INCOME
-123.75%
-73.3 M OPERATING CASH FLOW
-238.20%
184 M INVESTING CASH FLOW
231.57%
15.8 M FINANCING CASH FLOW
1.91%
155 M REVENUE
3.15%
-32.1 M OPERATING INCOME
4.51%
-30.6 M NET INCOME
8.40%
10.4 M OPERATING CASH FLOW
703.26%
10.2 M INVESTING CASH FLOW
102.72%
100 K FINANCING CASH FLOW
-99.89%
Balance Sheet Decomposition NovoCure Limited
image
Current Assets 1.03 B
Cash & Short-Term Investments 911 M
Receivables 61.2 M
Other Current Assets 62.6 M
Non-Current Assets 112 M
Long-Term Investments 0
PP&E 97.7 M
Other Non-Current Assets 14 M
Current Liabilities 179 M
Accounts Payable 94.4 M
Short-Term Debt 0
Other Current Liabilities 84.7 M
Non-Current Liabilities 605 M
Long-Term Debt 596 M
Other Non-Current Liabilities 8.28 M
EFFICIENCY
Earnings Waterfall NovoCure Limited
image
Revenue 509 M
Cost Of Revenue 128 M
Gross Profit 381 M
Operating Expenses 614 M
Operating Income -233 M
Other Expenses -25.8 M
Net Income -207 M
RATIOS
74.81% GROSS MARGIN
74.81%
-45.72% OPERATING MARGIN
-45.72%
-40.65% NET MARGIN
-40.65%
-57.12% ROE
-57.12%
-18.06% ROA
-18.06%
-27.00% ROIC
-27.00%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis NovoCure Limited
image
Net Income -207 M
Depreciation & Amortization 11 M
Capital Expenditures -27.1 M
Stock-Based Compensation 116 M
Change in Working Capital 29.6 M
Others -28.2 M
Free Cash Flow -100 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets NovoCure Limited
image
Wall Street analysts predict an average 1-year price target for NVCR of $26.4 , with forecasts ranging from a low of $14.5 to a high of $42 .
NVCR Lowest Price Target Wall Street Target
14.5 USD -9.99%
NVCR Average Price Target Wall Street Target
26.4 USD 63.61%
NVCR Highest Price Target Wall Street Target
42 USD 160.71%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership NovoCure Limited
image
Sold
0-3 MONTHS
25.6 K USD 3
3-6 MONTHS
82.9 K USD 4
6-9 MONTHS
164 K USD 2
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 weeks ago
Nov 02, 2024
Sell 734 USD
Paravasthu Mukund
Chief Operating Officer
- 44
16.6858 USD
2 weeks ago
Oct 31, 2024
Sell 12.8 K USD
Puri Michal Nath
Chief Human Resources Officer
- 810
15.7922 USD
2 weeks ago
Nov 01, 2024
Sell 9.53 K USD
Leonard Frank X
EVP, Pres., Novocure Oncology
- 598
15.9377 USD
2 weeks ago
Nov 01, 2024
Sell 2.54 K USD
Paravasthu Mukund
Chief Operating Officer
- 160
15.8776 USD
3 months ago
Aug 02, 2024
Sell 13.9 K USD
Cordova Ashley
Chief Financial Officer
- 688
20.1416 USD
5 months ago
Jun 04, 2024
Sell 23 K USD
VERNON W ANTHONY
Director
- 964
23.893 USD
5 months ago
Jun 04, 2024
Sell 23 K USD
Scannell Timothy J
Director
- 964
23.8874 USD
5 months ago
Jun 04, 2024
Sell 23 K USD
LEUNG GABRIEL
Director
- 964
23.8851 USD
8 months ago
Mar 01, 2024
Sell 33.8 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2107
16.0269 USD
8 months ago
Mar 04, 2024
Sell 19.5 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 1217
16.01 USD
8 months ago
Mar 01, 2024
Sell 26.9 K USD
Leonard Frank X
EVP, Pres., Novocure Oncology
- 1679
16.0269 USD
8 months ago
Mar 04, 2024
Sell 13.4 K USD
Leonard Frank X
EVP, Pres., Novocure Oncology
- 840
16.01 USD
8 months ago
Feb 28, 2024
Sell 33.5 K USD
Leonard Frank X
EVP, Pres., Novocure Oncology
- 2078
16.1428 USD
8 months ago
Feb 28, 2024
Sell 37.2 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2303
16.1428 USD
1 year ago
Nov 07, 2023
Sell 4.83 K USD
Shah Pritesh
Chief Growth Officer
- 382
12.65 USD
1 year ago
Sep 01, 2023
Sell 19.3 K USD
Cordova Ashley
Chief Financial Officer
- 883
21.8172 USD
1 year ago
Sep 01, 2023
Sell 6.41 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 294
21.8172 USD
1 year ago
Sep 01, 2023
Sell 5.96 K USD
Shah Pritesh
Chief Growth Officer
- 273
21.8172 USD
1 year ago
Aug 02, 2023
Sell 34.6 K USD
Cordova Ashley
Chief Financial Officer
- 1144
30.2511 USD
1 year ago
Mar 03, 2023
Sell 335 K USD
Leonard Frank X
President, CNS Cancers US
- 4403
76.1594 USD
1 year ago
Mar 03, 2023
Sell 67.6 K USD
Leonard Frank X
President, CNS Cancers US
- 888
76.1594 USD
1 year ago
Mar 07, 2023
Sell 450 K USD
Leonard Frank X
President, CNS Cancers US
- 6003
74.9968 USD
1 year ago
Mar 07, 2023
Sell 175 K USD
Leonard Frank X
President, CNS Cancers US
- 2315
75.5937 USD
1 year ago
Mar 03, 2023
Sell 120 K USD
Shah Pritesh
Chief Growth Officer
- 1570
76.1594 USD
1 year ago
Mar 03, 2023
Sell 224 K USD
Shah Pritesh
Chief Growth Officer
- 2942
76.1594 USD
1 year ago
Mar 03, 2023
Sell 1.29 M USD
Shah Pritesh
Chief Growth Officer
- 16909
76.1594 USD
1 year ago
Mar 03, 2023
Sell 269 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 3528
76.1594 USD
1 year ago
Mar 03, 2023
Sell 129 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 1692
76.1594 USD
1 year ago
Mar 03, 2023
Sell 1.55 M USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 20415
76.1594 USD
1 year ago
Mar 03, 2023
Sell 360 K USD
Cordova Ashley
Chief Financial Officer
- 4730
76.1594 USD
1 year ago
Mar 03, 2023
Sell 59 K USD
Cordova Ashley
Chief Financial Officer
- 775
76.1594 USD
1 year ago
Mar 03, 2023
Sell 45.2 K USD
Burke William Patrick
Chief Human Resources Officer
- 593
76.1594 USD
1 year ago
Mar 02, 2023
Sell 21.2 K USD
Burke William Patrick
Chief Human Resources Officer
- 281
75.2779 USD
1 year ago
Mar 02, 2023
Sell 70.5 K USD
Shah Pritesh
Chief Growth Officer
- 937
75.2779 USD
1 year ago
Mar 02, 2023
Sell 91.3 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 1213
75.2779 USD
1 year ago
Mar 02, 2023
Sell 79.4 K USD
Cordova Ashley
Chief Financial Officer
- 1055
75.2779 USD
1 year ago
Mar 03, 2023
Sell 160 K USD
Leonard Frank X
President, CNS Cancers US
- 2059
77.6391 USD
1 year ago
Mar 02, 2023
Sell 63.5 K USD
Leonard Frank X
President, CNS Cancers US
- 844
75.2779 USD
1 year ago
Mar 02, 2023
Sell 286 K USD
Leonard Frank X
President, CNS Cancers US
- 3799
75.3235 USD
1 year ago
Mar 02, 2023
Sell 23.4 K USD
Leonard Frank X
President, CNS Cancers US
- 308
76.0511 USD
1 year ago
Mar 01, 2023
Sell 129 K USD
Leonard Frank X
President, CNS Cancers US
- 1684
76.3624 USD
1 year ago
Mar 01, 2023
Sell 147 K USD
Shah Pritesh
Chief Growth Officer
- 1923
76.3624 USD
1 year ago
Mar 01, 2023
Sell 168 K USD
Cordova Ashley
Chief Financial Officer
- 2198
76.3624 USD
1 year ago
Mar 01, 2023
Sell 57.7 K USD
Burke William Patrick
Chief Human Resources Officer
- 755
76.3624 USD
1 year ago
Mar 01, 2023
Sell 165 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2164
76.3624 USD
1 year ago
Jan 05, 2023
Sell 234 K USD
Weinberg Uri
Chief Science Officer
- 1946
120 USD
1 year ago
Jan 05, 2023
Sell 283 K USD
Weinberg Uri
Chief Science Officer
- 2617
108 USD
1 year ago
Jan 05, 2023
Sell 144 K USD
Weinberg Uri
Chief Science Officer
- 1201
120 USD
1 year ago
Jan 05, 2023
Sell 279 K USD
Leonard Frank X
President, CNS Cancers US
- 2345
119.0077 USD
1 year ago
Jan 05, 2023
Sell 45 K USD
Leonard Frank X
President, CNS Cancers US
- 417
108 USD
1 year ago
Jan 05, 2023
Sell 60.5 K USD
Leonard Frank X
President, CNS Cancers US
- 526
115.0348 USD
1 year ago
Jan 05, 2023
Sell 862 K USD
Leonard Frank X
President, CNS Cancers US
- 7183
120 USD
1 year ago
Jan 05, 2023
Sell 41.8 K USD
Shah Pritesh
Chief Commercial Officer
- 387
108 USD
1 year ago
Jan 05, 2023
Sell 931 K USD
Danziger Asaf
Chief Executive Officer
- 8369
111.2338 USD
1 year ago
Jan 05, 2023
Sell 226 K USD
Danziger Asaf
Chief Executive Officer
- 2000
112.8632 USD
1 year ago
Jan 05, 2023
Sell 522 K USD
Danziger Asaf
Chief Executive Officer
- 4568
114.3524 USD
1 year ago
Jan 05, 2023
Sell 427 K USD
Danziger Asaf
Chief Executive Officer
- 3702
115.2113 USD
1 year ago
Jan 05, 2023
Sell 162 K USD
Danziger Asaf
Chief Executive Officer
- 1395
116.0618 USD
1 year ago
Jan 05, 2023
Sell 117 K USD
Danziger Asaf
Chief Executive Officer
- 999
117.0111 USD
1 year ago
Jan 05, 2023
Sell 252 K USD
Danziger Asaf
Chief Executive Officer
- 2123
118.4714 USD
1 year ago
Jan 05, 2023
Sell 160 K USD
Danziger Asaf
Chief Executive Officer
- 1344
119.3493 USD
1 year ago
Jan 05, 2023
Sell 20.2 M USD
Danziger Asaf
Chief Executive Officer
- 187500
108 USD
2 years ago
Oct 13, 2022
Sell 513 K USD
Leonard Frank X
President, CNS Cancers US
- 6754
76.01 USD
2 years ago
Oct 06, 2022
Sell 570 K USD
Leonard Frank X
President, CNS Cancers US
- 6754
84.37 USD
2 years ago
Sep 29, 2022
Sell 522 K USD
Leonard Frank X
President, CNS Cancers US
- 6754
77.35 USD
2 years ago
Sep 22, 2022
Sell 520 K USD
Leonard Frank X
President, CNS Cancers US
- 6754
77 USD
2 years ago
Sep 15, 2022
Sell 590 K USD
Leonard Frank X
Chief Development Officer
- 6754
87.31 USD
2 years ago
Sep 15, 2022
Sell 497 K USD
Leonard Frank X
Chief Development Officer
- 5517
90 USD
2 years ago
Sep 08, 2022
Sell 550 K USD
Leonard Frank X
Chief Development Officer
- 6754
81.48 USD
2 years ago
Sep 09, 2022
Sell 164 K USD
Leonard Frank X
Chief Development Officer
- 1863
88 USD
2 years ago
Sep 06, 2022
Sell 109 K USD
Leonard Frank X
Chief Development Officer
- 1384
78.57 USD
2 years ago
Sep 02, 2022
Sell 56.7 K USD
Burke William Patrick
Chief Human Resources Officer
- 718
79.037 USD
2 years ago
Sep 02, 2022
Sell 69.9 K USD
Cordova Ashley
Chief Financial Officer
- 885
79.037 USD
2 years ago
Sep 02, 2022
Sell 23.4 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 296
79.037 USD
2 years ago
Sep 02, 2022
Sell 21.3 K USD
Shah Pritesh
Chief Commercial Officer
- 269
79.037 USD
2 years ago
Sep 01, 2022
Sell 135 K USD
Leonard Frank X
Chief Development Officer
- 1750
76.958 USD
2 years ago
Aug 03, 2022
Sell 40 K USD
Benaim Ely
Chief Medical Officer
- 563
71.09 USD
2 years ago
Aug 03, 2022
Sell 399 K USD
Benaim Ely
Chief Medical Officer
- 5396
74 USD
2 years ago
Aug 02, 2022
Sell 58.3 K USD
DOYLE WILLIAM F
Executive Chairman
- 837
69.659 USD
2 years ago
Aug 02, 2022
Sell 30.4 K USD
Benaim Ely
Chief Medical Officer
- 437
69.659 USD
2 years ago
Aug 02, 2022
Sell 28.8 K USD
Leonard Frank X
Chief Development Officer
- 414
69.659 USD
2 years ago
Jun 10, 2022
Sell 28.3 K USD
HILLEMAN JERYL L
director:
- 407
69.61 USD
2 years ago
May 10, 2022
Sell 135 K USD
Benaim Ely
Chief Medical Officer
- 2070
65.158 USD
2 years ago
May 10, 2022
Sell 131 K USD
Benaim Ely
Chief Medical Officer
- 2135
61.25 USD
2 years ago
Mar 09, 2022
Sell 261 K USD
Shah Pritesh
Chief Commercial Officer
- 3669
71.19 USD
2 years ago
Mar 07, 2022
Sell 174 K USD
Shah Pritesh
Chief Commercial Officer
- 2481
70.1 USD
2 years ago
Mar 08, 2022
Sell 52.2 K USD
Leonard Frank X
Chief Development Officer
- 744
70.1 USD
2 years ago
Mar 08, 2022
Sell 72.7 K USD
Burke William Patrick
Chief Human Resources Officer
- 1037
70.1 USD
2 years ago
Mar 08, 2022
Sell 205 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2923
70.1 USD
2 years ago
Mar 08, 2022
Sell 53.2 K USD
Cordova Ashley
Chief Financial Officer
- 759
70.1 USD
2 years ago
Mar 08, 2022
Sell 164 K USD
Longsworth Todd Christopher
General Counsel
- 2339
70.1 USD
2 years ago
Mar 08, 2022
Sell 167 K USD
DOYLE WILLIAM F
Executive Chairman
- 2385
70.1 USD
2 years ago
Mar 03, 2022
Sell 81.5 K USD
Longsworth Todd Christopher
General Counsel
- 1094
74.498 USD
2 years ago
Mar 03, 2022
Sell 39.1 K USD
Cordova Ashley
Chief Financial Officer
- 556
70.407 USD
2 years ago
Mar 03, 2022
Sell 135 K USD
Shah Pritesh
Chief Commercial Officer
- 1914
70.407 USD
2 years ago
Mar 03, 2022
Sell 59.8 K USD
Benaim Ely
Chief Medical Officer
- 803
74.498 USD
2 years ago
Mar 03, 2022
Sell 106 K USD
Benaim Ely
Chief Medical Officer
- 1510
70.407 USD
2 years ago
Mar 03, 2022
Sell 72.2 K USD
Burke William Patrick
Chief Human Resources Officer
- 1026
70.407 USD
2 years ago
Mar 03, 2022
Sell 96.9 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 1301
74.498 USD
2 years ago
Mar 03, 2022
Sell 181 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2569
70.407 USD
2 years ago
Mar 03, 2022
Sell 39.1 K USD
Leonard Frank X
Chief Development Officer
- 555
70.407 USD
2 years ago
Jan 03, 2022
Sell 30.3 K USD
Burke William Patrick
Chief Human Resources Officer
- 399
76.03 USD
2 years ago
Jan 03, 2022
Sell 69.9 K USD
Burke William Patrick
Chief Human Resources Officer
- 919
76.087 USD
2 years ago
Jan 03, 2022
Sell 200 K USD
Burke William Patrick
Chief Human Resources Officer
- 2633
75.96 USD
2 years ago
Nov 26, 2021
Bought 10 K USD
Danziger Asaf
Chief Executive Officer
+ 104
96.5 USD
2 years ago
Nov 26, 2021
Bought 103 K USD
Danziger Asaf
Chief Executive Officer
+ 1000
103.37 USD
2 years ago
Nov 26, 2021
Bought 396 K USD
Danziger Asaf
Chief Executive Officer
+ 3870
102.36 USD
3 years ago
Nov 02, 2021
Sell 22.4 K USD
Cordova Ashley
Chief Financial Officer
- 209
107.276 USD
3 years ago
Sep 02, 2021
Sell 74.6 K USD
Leonard Frank X
Chief Development Officer
- 540
138.232 USD
3 years ago
Sep 02, 2021
Sell 114 K USD
Cordova Ashley
Chief Financial Officer
- 828
138.232 USD
3 years ago
Sep 02, 2021
Sell 25 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 181
138.232 USD
3 years ago
Sep 02, 2021
Sell 21.6 K USD
Shah Pritesh
Chief Commercial Officer
- 156
138.232 USD
3 years ago
Sep 03, 2021
Sell 44.4 K USD
Shah Pritesh
Chief Commercial Officer
- 321
138.273 USD
3 years ago
Sep 03, 2021
Sell 20.9 K USD
Shah Pritesh
Chief Commercial Officer
- 150
139.238 USD
3 years ago
Sep 03, 2021
Sell 4.21 K USD
Shah Pritesh
Chief Commercial Officer
- 30
140.18 USD
3 years ago
Aug 12, 2021
Sell 836 K USD
Cordova Ashley
Chief Financial Officer
- 5927
141.06 USD
3 years ago
Aug 12, 2021
Sell 1.13 M USD
Cordova Ashley
Chief Financial Officer
- 8026
140.902 USD
3 years ago
Aug 12, 2021
Sell 367 K USD
Cordova Ashley
Chief Financial Officer
- 2606
140.9 USD
3 years ago
Aug 05, 2021
Sell 5.21 K USD
Madden Martin J.
Director
- 34
153.13 USD
3 years ago
Aug 04, 2021
Sell 307 K USD
Shah Pritesh
Chief Commercial Officer
- 2063
148.71 USD
3 years ago
Aug 05, 2021
Sell 152 K USD
LEUNG GABRIEL
Director
- 1000
152.5 USD
3 years ago
Aug 02, 2021
Sell 107 K USD
Leonard Frank X
Chief Development Officer
- 713
149.378 USD
3 years ago
Aug 03, 2021
Sell 49 K USD
Leonard Frank X
Chief Development Officer
- 328
149.43 USD
3 years ago
Aug 03, 2021
Sell 247 K USD
Shah Pritesh
Chief Commercial Officer
- 1654
149.43 USD
3 years ago
Aug 02, 2021
Sell 149 K USD
DOYLE WILLIAM F
Executive Chairman
- 995
149.378 USD
3 years ago
Aug 03, 2021
Sell 69.7 K USD
Benaim Ely
Chief Medical Officer
- 464
150.11 USD
3 years ago
Jul 30, 2021
Sell 103 K USD
Benaim Ely
Chief Medical Officer
- 651
158.96 USD
3 years ago
Aug 02, 2021
Sell 80.1 K USD
Benaim Ely
Chief Medical Officer
- 536
149.378 USD
3 years ago
Jul 06, 2021
Sell 184 K USD
LEUNG GABRIEL
Director
- 1000
183.54 USD
3 years ago
Jun 10, 2021
Sell 5.06 M USD
Shah Pritesh
Chief Commercial Officer
- 23540
215 USD
3 years ago
Jun 07, 2021
Sell 205 K USD
LEUNG GABRIEL
Director
- 1000
204.55 USD
3 years ago
May 27, 2021
Sell 367 K USD
Benaim Ely
Chief Medical Officer
- 1833
200 USD
3 years ago
May 12, 2021
Sell 351 K USD
Benaim Ely
Chief Medical Officer
- 1943
180.48 USD
3 years ago
May 10, 2021
Sell 348 K USD
Benaim Ely
Chief Medical Officer
- 1833
189.65 USD
3 years ago
May 11, 2021
Sell 407 K USD
Benaim Ely
Chief Medical Officer
- 2262
180.118 USD
3 years ago
May 10, 2021
Sell 729 K USD
Weinberg Uri
Chief Science Officer
- 3846
189.65 USD
3 years ago
May 10, 2021
Sell 342 K USD
Weinberg Uri
Chief Science Officer
- 1804
189.65 USD
3 years ago
May 05, 2021
Sell 258 K USD
Shah Pritesh
Chief Commercial Officer
- 1290
199.67 USD
3 years ago
May 05, 2021
Sell 200 K USD
LEUNG GABRIEL
Director
- 1000
199.67 USD
3 years ago
May 04, 2021
Sell 209 K USD
Shah Pritesh
Chief Commercial Officer
- 1043
200.856 USD
3 years ago
Apr 13, 2021
Sell 268 K USD
DOYLE WILLIAM F
Executive Chairman
- 1400
191.263 USD
3 years ago
Apr 13, 2021
Sell 366 K USD
DOYLE WILLIAM F
Executive Chairman
- 1900
192.524 USD
3 years ago
Apr 13, 2021
Sell 405 K USD
DOYLE WILLIAM F
Executive Chairman
- 2090
193.571 USD
3 years ago
Apr 13, 2021
Sell 312 K USD
DOYLE WILLIAM F
Executive Chairman
- 1600
194.94 USD
3 years ago
Apr 13, 2021
Sell 1.73 M USD
DOYLE WILLIAM F
Executive Chairman
- 8814
196.073 USD
3 years ago
Apr 13, 2021
Sell 4.79 M USD
DOYLE WILLIAM F
Executive Chairman
- 24338
197.003 USD
3 years ago
Apr 13, 2021
Sell 2.69 M USD
DOYLE WILLIAM F
Executive Chairman
- 13612
197.831 USD
3 years ago
Apr 13, 2021
Sell 2.1 M USD
DOYLE WILLIAM F
Executive Chairman
- 10563
198.977 USD
3 years ago
Apr 13, 2021
Sell 866 K USD
DOYLE WILLIAM F
Executive Chairman
- 4338
199.713 USD
3 years ago
Apr 13, 2021
Sell 831 K USD
DOYLE WILLIAM F
Executive Chairman
- 4125
201.546 USD
3 years ago
Apr 13, 2021
Sell 887 K USD
DOYLE WILLIAM F
Executive Chairman
- 4388
202.158 USD
3 years ago
Apr 13, 2021
Sell 519 K USD
DOYLE WILLIAM F
Executive Chairman
- 2555
203.253 USD
3 years ago
Apr 13, 2021
Sell 403 K USD
DOYLE WILLIAM F
Executive Chairman
- 1972
204.277 USD
3 years ago
Apr 13, 2021
Sell 329 K USD
DOYLE WILLIAM F
Executive Chairman
- 1600
205.431 USD
3 years ago
Apr 13, 2021
Sell 265 K USD
DOYLE WILLIAM F
Executive Chairman
- 1284
206.352 USD
3 years ago
Apr 13, 2021
Sell 935 K USD
DOYLE WILLIAM F
Executive Chairman
- 4500
207.804 USD
3 years ago
Apr 13, 2021
Sell 461 K USD
DOYLE WILLIAM F
Executive Chairman
- 2200
209.343 USD
3 years ago
Apr 13, 2021
Sell 110 K USD
DOYLE WILLIAM F
Executive Chairman
- 521
210.181 USD
3 years ago
Apr 13, 2021
Sell 127 K USD
DOYLE WILLIAM F
Executive Chairman
- 600
211.276 USD
3 years ago
Apr 13, 2021
Sell 320 K USD
DOYLE WILLIAM F
Executive Chairman
- 1500
213.347 USD
3 years ago
Apr 13, 2021
Sell 107 K USD
DOYLE WILLIAM F
Executive Chairman
- 500
214.665 USD
3 years ago
Apr 13, 2021
Sell 130 K USD
DOYLE WILLIAM F
Executive Chairman
- 600
216.694 USD
3 years ago
Apr 13, 2021
Sell 19.2 M USD
Danziger Asaf
Chief Executive Officer
- 97973
196.3431 USD
3 years ago
Apr 13, 2021
Sell 693 K USD
LEUNG GABRIEL
Director
- 3500
198.01 USD
3 years ago
Apr 13, 2021
Sell 500 K USD
LEUNG GABRIEL
Director
- 2500
200 USD
3 years ago
Apr 13, 2021
Sell 695 K USD
Benaim Ely
Chief Medical Officer
- 3474
200 USD
3 years ago
Mar 23, 2021
Sell 397 K USD
Weinberg Uri
Chief Science Officer
- 2835
140 USD
4 years ago
Feb 28, 2020
Sell 265 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 3670
72.215 USD
3 years ago
Apr 01, 2021
Sell 1.06 M USD
DOYLE WILLIAM F
Executive Chairman
- 7928
134.12 USD
3 years ago
Mar 23, 2021
Sell 545 K USD
Weinberg Uri
Chief Science Officer
- 3892
140 USD
3 years ago
Mar 08, 2021
Sell 344 K USD
Shah Pritesh
Chief Commercial Officer
- 2627
130.806 USD
3 years ago
Mar 09, 2021
Sell 462 K USD
Shah Pritesh
Chief Commercial Officer
- 3524
131.09 USD
3 years ago
Mar 08, 2021
Sell 100 K USD
Cordova Ashley
Chief Financial Officer
- 765
130.806 USD
3 years ago
Mar 08, 2021
Sell 314 K USD
Longsworth Todd Christopher
General Counsel
- 2404
130.806 USD
3 years ago
Mar 08, 2021
Sell 100 K USD
Leonard Frank X
Chief Development Officer
- 765
130.806 USD
3 years ago
Mar 08, 2021
Sell 393 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 3004
130.806 USD
3 years ago
Mar 05, 2021
Sell 598 K USD
Shah Pritesh
Chief Commercial Officer
- 4550
131.53 USD
3 years ago
Mar 05, 2021
Sell 384 K USD
Benaim Ely
Chief Medical Officer
- 2918
131.53 USD
3 years ago
Mar 04, 2021
Sell 530 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 3854
137.554 USD
3 years ago
Mar 04, 2021
Sell 424 K USD
Longsworth Todd Christopher
General Counsel
- 3084
137.554 USD
3 years ago
Mar 04, 2021
Sell 78 K USD
Leonard Frank X
Chief Development Officer
- 567
137.554 USD
3 years ago
Mar 04, 2021
Sell 78 K USD
Cordova Ashley
Chief Financial Officer
- 567
137.554 USD
3 years ago
Mar 03, 2021
Sell 524 K USD
Benaim Ely
Chief Medical Officer
- 3475
150.78 USD
3 years ago
Mar 04, 2021
Sell 260 K USD
Benaim Ely
Chief Medical Officer
- 1888
137.554 USD
3 years ago
Mar 03, 2021
Sell 328 K USD
Shah Pritesh
Chief Commercial Officer
- 2174
150.78 USD
3 years ago
Mar 04, 2021
Sell 366 K USD
Shah Pritesh
Chief Commercial Officer
- 2658
137.554 USD
3 years ago
Mar 02, 2021
Sell 65.4 K USD
Leonard Frank X
Chief Development Officer
- 430
152.053 USD
3 years ago
Mar 02, 2021
Sell 65.1 K USD
Cordova Ashley
Chief Financial Officer
- 428
152.053 USD
3 years ago
Mar 02, 2021
Sell 364 K USD
GROENHUYSEN WILHELMUS CM
Chief Operating Officer
- 2392
152.053 USD
3 years ago
Mar 02, 2021
Sell 139 K USD
Shah Pritesh
Chief Commercial Officer
- 912
152.053 USD
3 years ago
Mar 02, 2021
Sell 358 K USD
Longsworth Todd Christopher
General Counsel
- 2355
152.053 USD
3 years ago
Feb 22, 2021
Sell 1.14 M USD
Weinberg Uri
Chief Science Officer
- 6500
175.5 USD
3 years ago
Jan 15, 2021
Sell 419 K USD
Longsworth Todd Christopher
General Counsel
- 2499
167.761 USD
3 years ago
Jan 15, 2021
Sell 135 K USD
Longsworth Todd Christopher
General Counsel
- 800
168.804 USD
3 years ago
Jan 15, 2021
Sell 365 K USD
Longsworth Todd Christopher
General Counsel
- 2148
169.76 USD
3 years ago
Jan 15, 2021
Sell 473 K USD
Longsworth Todd Christopher
General Counsel
- 2761
171.184 USD
3 years ago
Jan 15, 2021
Sell 1.74 M USD
Longsworth Todd Christopher
General Counsel
- 10110
171.859 USD
3 years ago
Jan 15, 2021
Sell 225 K USD
Longsworth Todd Christopher
General Counsel
- 1300
172.952 USD
3 years ago
Jan 15, 2021
Sell 278 K USD
Longsworth Todd Christopher
General Counsel
- 1600
173.878 USD
3 years ago
Jan 15, 2021
Sell 298 K USD
Longsworth Todd Christopher
General Counsel
- 1700
175.136 USD
3 years ago
Jan 15, 2021
Sell 70.4 K USD
Longsworth Todd Christopher
General Counsel
- 400
175.981 USD
3 years ago
Jan 15, 2021
Sell 390 K USD
Longsworth Todd Christopher
General Counsel
- 2200
177.305 USD
3 years ago
Jan 15, 2021
Sell 179 K USD
Longsworth Todd Christopher
General Counsel
- 1000
178.675 USD
3 years ago
Jan 15, 2021
Sell 161 K USD
Longsworth Todd Christopher
General Counsel
- 900
179.368 USD
3 years ago
Jan 15, 2021
Sell 587 K USD
Longsworth Todd Christopher
General Counsel
- 3500
167.774 USD
3 years ago
Jan 15, 2021
Sell 305 K USD
Longsworth Todd Christopher
General Counsel
- 1800
169.194 USD
3 years ago
Jan 15, 2021
Sell 432 K USD
Longsworth Todd Christopher
General Counsel
- 2542
169.933 USD
3 years ago
Jan 15, 2021
Sell 827 K USD
Longsworth Todd Christopher
General Counsel
- 4826
171.318 USD
3 years ago
Jan 15, 2021
Sell 2.06 M USD
Longsworth Todd Christopher
General Counsel
- 11985
171.903 USD
3 years ago
Jan 15, 2021
Sell 294 K USD
Longsworth Todd Christopher
General Counsel
- 1700
173.1 USD
3 years ago
Jan 15, 2021
Sell 436 K USD
Longsworth Todd Christopher
General Counsel
- 2502
174.063 USD
3 years ago
Jan 15, 2021
Sell 386 K USD
Longsworth Todd Christopher
General Counsel
- 2200
175.279 USD
3 years ago
Jan 15, 2021
Sell 70.5 K USD
Longsworth Todd Christopher
General Counsel
- 400
176.215 USD
3 years ago
Jan 15, 2021
Sell 504 K USD
Longsworth Todd Christopher
General Counsel
- 2841
177.331 USD
3 years ago
Jan 15, 2021
Sell 161 K USD
Longsworth Todd Christopher
General Counsel
- 900
178.498 USD
3 years ago
Jan 15, 2021
Sell 215 K USD
Longsworth Todd Christopher
General Counsel
- 1200
179.301 USD
3 years ago
Dec 21, 2020
Sell 102 K USD
Benaim Ely
Chief Medical Officer
- 651
156.71 USD
3 years ago
Dec 18, 2020
Sell 416 K USD
HILLEMAN JERYL L
Director
- 2500
166.4 USD
3 years ago
Dec 18, 2020
Sell 3.29 M USD
Danziger Asaf
Chief Executive Officer
- 21207
155.232 USD
3 years ago
Dec 18, 2020
Sell 3.36 M USD
Danziger Asaf
Chief Executive Officer
- 21612
155.24 USD
3 years ago
Dec 18, 2020
Sell 3.79 M USD
Danziger Asaf
Chief Executive Officer
- 24286
156.091 USD
3 years ago
Dec 18, 2020
Sell 3.9 M USD
Danziger Asaf
Chief Executive Officer
- 24973
156.083 USD
3 years ago
Dec 18, 2020
Sell 3.71 M USD
Danziger Asaf
Chief Executive Officer
- 23601
157.007 USD
3 years ago
Dec 18, 2020
Sell 3.87 M USD
Danziger Asaf
Chief Executive Officer
- 24656
157.037 USD
3 years ago
Dec 18, 2020
Sell 1.45 M USD
Danziger Asaf
Chief Executive Officer
- 9183
158.094 USD
3 years ago
Dec 18, 2020
Sell 1.59 M USD
Danziger Asaf
Chief Executive Officer
- 10077
158.064 USD
3 years ago
Dec 18, 2020
Sell 717 K USD
Danziger Asaf
Chief Executive Officer
- 4500
159.323 USD
3 years ago
Dec 18, 2020
Sell 763 K USD
Danziger Asaf
Chief Executive Officer
- 4790
159.27 USD
3 years ago
Dec 18, 2020
Sell 1.94 M USD
Danziger Asaf
Chief Executive Officer
- 12092
160.25 USD
3 years ago
Dec 18, 2020
Sell 1.87 M USD
Danziger Asaf
Chief Executive Officer
- 11686
160.27 USD
3 years ago
Dec 18, 2020
Sell 563 K USD
Danziger Asaf
Chief Executive Officer
- 3500
160.994 USD
3 years ago
Dec 18, 2020
Sell 647 K USD
Danziger Asaf
Chief Executive Officer
- 4014
161.106 USD
3 years ago
Dec 18, 2020
Sell 231 K USD
Danziger Asaf
Chief Executive Officer
- 1426
162.173 USD
7. News
NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by. seekingalpha.com - 2 weeks ago
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago. zacks.com - 2 weeks ago
Novocure Appoints Christoph Brackmann as Chief Financial Officer ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer. businesswire.com - 2 weeks ago
Novocure Reports Third Quarter 2024 Financial Results ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results. businesswire.com - 2 weeks ago
NovoCure: There Is Still More Upside On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy. seekingalpha.com - 1 month ago
FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients On Tuesday, the FDA approved NovoCure's NVCR Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. benzinga.com - 1 month ago
NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains? NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. zacks.com - 1 month ago
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a. businesswire.com - 1 month ago
Novocure to Report Third Quarter 2024 Financial Results ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. businesswire.com - 1 month ago
Why NovoCure Stock Dived by 13% This Week The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025. fool.com - 2 months ago
Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 3 months ago
8. Profile Summary

NovoCure Limited NVCR

image
COUNTRY JE
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 1.74 B
Dividend Yield 0.00%
Description NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Contact No. 4 The Forum, Saint Helier, JE2 4UF https://www.novocure.com
IPO Date Oct. 1, 2015
Employees 1453
Officers Mr. Michael Puri Chief Human Resources Officer Mr. Frank Leonard Executive Vice President & President of Novocure Oncology Prof. Yoram Palti M.D., Ph.D. Founder & Chief Technology Officer Mr. Barak Ben Arye General Counsel Mr. Asaf Danziger Chief Executive Officer & Director Mr. Mukund Paravasthu Chief Operating Officer Dr. Moshe Giladi Ph.D. Chief Science Officer Ms. Ingrid Goldberg Vice President of Investor Relations Mr. William F. Doyle Executive Chairman Ms. Ashley Cordova Chief Financial Officer